Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

257 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk factors for postoperative cervical haematoma in patients undergoing thyroidectomy: a retrospective, multicenter, international analysis (REDHOT study).
Canu GL, Medas F, Cappellacci F, Rossi L, Gjeloshi B, Sessa L, Pennestrì F, Djafarrian R, Mavromati M, Kotsovolis G, Pliakos I, Di Filippo G, Lazzari G, Vaccaro C, Izzo M, Boi F, Brazzarola P, Feroci F, Demarchi MS, Papavramidis T, Materazzi G, Raffaelli M, Calò PG; REDHOT Study Collaborative Group. Canu GL, et al. Front Surg. 2023 Oct 2;10:1278696. doi: 10.3389/fsurg.2023.1278696. eCollection 2023. Front Surg. 2023. PMID: 37850042 Free PMC article.
Assessment of the risk of malignancy in Bethesda III thyroid nodules: a comprehensive review.
Rao KN, Randolph GW, Lopez F, Zafereo M, Coca-Pelaz A, Piazza C, Dange P, Rodrigo JP, Stenman G, de Keizer B, Nixon I, Sinha S, Leboulleux S, Mäkitie AA, Agaimy A, Thompson L, Ferlito A; This paper was written by members and invitees of the International Head and Neck Scientific Group. Rao KN, et al. Among authors: leboulleux s. Endocrine. 2024 Aug;85(2):473-492. doi: 10.1007/s12020-024-03737-z. Epub 2024 Feb 28. Endocrine. 2024. PMID: 38416380 Review.
Langerhans cell histiocytosis of the suprasellar region: diagnosis based on thyroid cytology.
Mavromati M, Caironi V, Saiji E, Vargas MI, Momjian S, Andrade-Lopes S, Gubert C, Demarchi MS, Mainta I, Jornayvaz FR, Samii K, Stalder G, Leboulleux S. Mavromati M, et al. Among authors: leboulleux s. Eur Thyroid J. 2024 May 30;13(3):e240011. doi: 10.1530/ETJ-24-0011. Print 2024 Jun 1. Eur Thyroid J. 2024. PMID: 38718824 Free PMC article.
Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial.
Leboulleux S, Bournaud C, Chougnet CN, Lamartina L, Zerdoud S, Do Cao C, Catargi B, Dygai I, Kelly A, Barge ML, Vera P, Rusu D, Schneegans O, Roux J, Raymond P, Benisvy D, Eberle MC, Bidault S, Nascimento C, Bastie D, Giraudet AL, Bardet S, Le Moullec N, Roudaut N, Drui D, Godbert Y, Zalzali M, Drutel A, Morel O, Velayoudom FL, Al Ghuzlan A, Schlumberger M, Buffet C, Borget I. Leboulleux S, et al. Lancet Diabetes Endocrinol. 2025 Jan;13(1):38-46. doi: 10.1016/S2213-8587(24)00276-6. Epub 2024 Nov 22. Lancet Diabetes Endocrinol. 2025. PMID: 39586309 Free article. Clinical Trial.
Biomarkers improving genetic and metastatic disease prediction in paraganglioma: insights from a prospective study.
Drossart T, Buffet A, Janbain A, Ottolenghi C, Amar L, Libé R, Drui D, Lussey-Lepoutre C, Mancini M, Lounis T, Guénégou-Arnoux A, Méatchi T, Bertherat J, Burnichon N, Favier J, Gimenez-Roqueplo AP; COMETE-TACTIC Study Group. Drossart T, et al. J Clin Endocrinol Metab. 2024 Nov 14:dgae797. doi: 10.1210/clinem/dgae797. Online ahead of print. J Clin Endocrinol Metab. 2024. PMID: 39541377
Prognostic value of total, free and lipoprotein fraction-bound plasma mitotane levels in advanced adrenocortical carcinoma: a prospective study of the ENDOCAN-COMETE-Cancer network.
Faron M, Naman A, Delahousse J, Hescot S, Hadoux J, Castinetti F, Drui D, Renoult-Pierre P, Libe R, Lamartina L, Leboulleux S, Al-Ghuzlan A, Lombès M, Paci A, Baudin E; For Endocan-Comete Network. Faron M, et al. Among authors: leboulleux s. J Endocrinol Invest. 2024 Aug 22. doi: 10.1007/s40618-024-02439-7. Online ahead of print. J Endocrinol Invest. 2024. PMID: 39172357
Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF).
Leboulleux S, Kapiteijn E, Litière S, Schöffski P, Godbert Y, Rodien P, Jarzab B, Salvatore D, Zanetta S, Capdevila J, Bastholt L, De La Fouchardiere C, Lalami Y, Bardet S, Cornélis F, Dedecjus M, Links T, Sents W, Schlumberger M, Locati DL, Newbold K. Leboulleux S, et al. Front Endocrinol (Lausanne). 2024 Jun 27;15:1403687. doi: 10.3389/fendo.2024.1403687. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39015176 Free PMC article. Clinical Trial.
257 results